You searched for: cabg (Engelska - Kroatiska)

major (non- cabg)
veliko (ne- cabg)

cabg-related bleeding
krvarenje vezano uz cabg

non-cabg plato major
ne-cabg plato velika

cabg post-operative safety studies
ispitivanja sigurnosti primjene nakon operacije ugradnje arteriokoronarne premosnice

non-cabg timi major bleeding event
ne-cabg timi veće krvarenje

table 2: non-cabg-related bleeding
tablica 2: krvarenje koje nije povezano sa cabg

non-cabg-related timi major or minor bleeding rates:
stope značajnih odnosno manjih krvarenja (prema timi kriterijima) nevezanih uz cabg:

in the phase 3 clinical trial, 437 patients underwent cabg during the course of the study.
u fazi iii kliničkog ispitivanja je u 437 bolesnika tijekom ispitivanja učinjen cabg.

patients received low-dose acetylsalicylic acid prior to randomization and throughout the two cabg surgery studies.
prije randomizacije i tijekom cijelog trajanja ta dva kirurška ispitivanja primjene kod operacije ugradnje arteriokoronarne premosnice bolesnici su primali nisku dozu acetilsalicilne kiseline.

in patients undergoing cabg, the incidence of bleeding was not increased by eptifibatide compared to the patients treated with placebo.
u bolesnika podvrgnutih cabg-u, incidencija krvarenja nije bila povišena primjenom eptifibatida u usporedbi s ispitanicima na placebu.

eptifibatide accord infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency cabg surgery or requires an intraortic balloon pump.
infuziju eptifibatid accord a treba odmah prekinuti ako nastupe okolnosti koje zahtijevaju primjenu trombolitičke terapije ili ako bolesnik mora pristupiti hitnoj ugradnji premosnice koronarne arterije (cabg) ili zahtijeva intraaortnu balon pumpu.

dynastat has not been studied in cardiovascular revascularization procedures other than cabg (coronary artery bypass graft procedures).
dynastat nije ispitan u drugim postupcima kardiovaskularne revaskularizacije osim kod cabg (ugradnja arteriokoronarne premosnice).

patients were managed according to the usual standards of the investigational site; frequencies of angiography, pci and cabg therefore differed widely from site to site and from country to country.
bolesnici su bili liječeni prema uobičajenim standardima ispitivačkog centra; učestalost angiografije, pci i cabg su se stoga dosta razlikovale od centra do centra i od zemlje do zemlje.

in addition, in fewer patients of the group treated with enoxaparin it was necessary to carry out revascularisation by using the method of percutaneous transluminal coronary angioplasty (ptca) or coronary artery bypass graft (cabg) (reduction of the risk of recurrent coronary heart disease, myocardial infarction or death by 15.8% on day 30 of treatment).
nadalje, u manjem broju bolesnika u skupini liječenoj enoksaparinom bilo je potrebno izvesti revaskularizaciju pomoću perkutane transluminalne koronarne angioplastike (ptca, engl. percutaneous transluminal coronary angioplasty) ili koronarne premosnice (cabg, coronary artery bypass graft (smanjenje rizika povrata koronarne bolesti srca, infarkta miokarda ili smrti za 15,8% na 30. dan liječenja).